Developing a UK sarcopenia registry: recruitment and baseline characteristics of the SarcNet pilot.
sarcopenia
older people
recruitment
registry
Journal
Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655
Informations de publication
Date de publication:
11 09 2021
11 09 2021
Historique:
received:
25
11
2020
revised:
01
03
2021
accepted:
19
03
2021
pubmed:
27
5
2021
medline:
24
9
2021
entrez:
26
5
2021
Statut:
ppublish
Résumé
sarcopenia registries are a potential method to meet the challenge of recruitment to sarcopenia trials. We tested the feasibility of setting up a UK sarcopenia registry, the feasibility of recruitment methods and sought to characterise the pilot registry population. six diverse UK sites took part, with potential participants aged 65 and over approached via mailshots from local primary care practices. Telephone pre-screening using the SARC-F score was followed by in-person screening and baseline visit. Co-morbidities, medications, grip strength, Short Physical Performance Battery, bioimpedance analysis, Geriatric Depression Score, Montreal Cognitive Assessment, Sarcopenia Quality of Life score were performed and permission sought for future recontact. Descriptive statistics for recruitment rates and baseline measures were generated; an embedded randomised trial examined the effect of a University logo on the primary care mailshot on recruitment rates. sixteen practices contributed a total of 3,508 letters. In total, 428 replies were received (12% response rate); 380 underwent telephone pre-screening of whom 215 (57%) were eligible to attend a screening visit; 150 participants were recruited (40% of those pre-screened) with 147 contributing baseline data. No significant difference was seen in response rates between mailshots with and without the logo (between-group difference 1.1% [95% confidence interval -1.0% to 3.4%], P = 0.31). The mean age of enrollees was 78 years; 72 (49%) were women. In total, 138/147 (94%) had probable sarcopenia on European Working Group on Sarcopenia 2019 criteria and 145/147 (98%) agreed to be recontacted about future studies. recruitment to a multisite UK sarcopenia registry is feasible, with high levels of consent for recontact.
Sections du résumé
BACKGROUND
sarcopenia registries are a potential method to meet the challenge of recruitment to sarcopenia trials. We tested the feasibility of setting up a UK sarcopenia registry, the feasibility of recruitment methods and sought to characterise the pilot registry population.
METHODS
six diverse UK sites took part, with potential participants aged 65 and over approached via mailshots from local primary care practices. Telephone pre-screening using the SARC-F score was followed by in-person screening and baseline visit. Co-morbidities, medications, grip strength, Short Physical Performance Battery, bioimpedance analysis, Geriatric Depression Score, Montreal Cognitive Assessment, Sarcopenia Quality of Life score were performed and permission sought for future recontact. Descriptive statistics for recruitment rates and baseline measures were generated; an embedded randomised trial examined the effect of a University logo on the primary care mailshot on recruitment rates.
RESULTS
sixteen practices contributed a total of 3,508 letters. In total, 428 replies were received (12% response rate); 380 underwent telephone pre-screening of whom 215 (57%) were eligible to attend a screening visit; 150 participants were recruited (40% of those pre-screened) with 147 contributing baseline data. No significant difference was seen in response rates between mailshots with and without the logo (between-group difference 1.1% [95% confidence interval -1.0% to 3.4%], P = 0.31). The mean age of enrollees was 78 years; 72 (49%) were women. In total, 138/147 (94%) had probable sarcopenia on European Working Group on Sarcopenia 2019 criteria and 145/147 (98%) agreed to be recontacted about future studies.
CONCLUSION
recruitment to a multisite UK sarcopenia registry is feasible, with high levels of consent for recontact.
Identifiants
pubmed: 34038519
pii: 6284387
doi: 10.1093/ageing/afab084
pmc: PMC8437066
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1762-1769Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Age Ageing. 2011 Jul;40(4):423-9
pubmed: 21624928
Age Ageing. 2014 Nov;43(6):748-59
pubmed: 25241753
Age Ageing. 2017 Mar 1;46(2):271-276
pubmed: 27789428
Adv Exp Med Biol. 2017;1031:97-124
pubmed: 29214567
Trials. 2018 Jan 04;19(1):6
pubmed: 29301558
Age Ageing. 2013 May;42(3):378-84
pubmed: 23384705
Eur Geriatr Med. 2020 Jun;11(3):433-441
pubmed: 32297269
Age Ageing. 2021 Jan 8;50(1):88-95
pubmed: 32706848
ERJ Open Res. 2016 Jan 20;2(1):
pubmed: 27730179
Biogerontology. 2019 Apr;20(2):241-248
pubmed: 30591980
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Br J Community Nurs. 2020 Mar 2;25(3):110-113
pubmed: 32160030
Expert Opin Pharmacother. 2019 Sep;20(13):1645-1657
pubmed: 31120352
Maturitas. 2017 Sep;103:16-22
pubmed: 28778327
Exp Gerontol. 2018 Nov;113:48-57
pubmed: 30261246
Cochrane Database Syst Rev. 2018 Feb 22;2:MR000013
pubmed: 29468635
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):485-500
pubmed: 30993881
J Frailty Aging. 2013;2(1):55-6
pubmed: 27070457
Clin Nutr. 2015 Aug;34(4):667-73
pubmed: 25103151
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
J Frailty Sarcopenia Falls. 2019 Sep 01;4(3):71-77
pubmed: 32300721
J Am Med Dir Assoc. 2015 Sep 1;16(9):740-7
pubmed: 26170041
J Gerontol A Biol Sci Med Sci. 2020 Jun 18;75(7):1324-1330
pubmed: 32157272